Biotechnology | Disease | FDA | Therapeutics
Regeneron’s Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis
On Nov. 18, 2026, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™…